Granted Patent
B2
US 12,533,355 · App. 18/478,482 · Granted Jan 27, 2026
Methods of treatment comprising administering lumateperone mono-tosylate capsules
Assignee:
INTRA-CELLULAR THERAPIES, INC.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present disclosure relates to pharmaceutical capsules comprising lumateperone, in free, or pharmaceutically acceptable salt form, optionally in combination with one or more additional therapeutic agents, processes for manufacture thereof and methods of use in the treatment or prophylaxis of disease.
Claims (30)
1 . A method for the treatment of a disease or disorder involving or mediated by the 5-HT 2A receptor, serotonin transporter (SERT), and/or dopamine D1/D2 receptor signaling pathways, comprising administering to a patient in need thereof a pharmaceutical capsule for oral administration, comprising lumateperone:
in mono-tosylate salt form, wherein the lumateperone mono-tosylate is in solid crystal form; and
wherein the capsule comprises a blend of 10 to 30% by weight of lumateperone mono-tosylate in solid crystal form, 60 to 90% by weight of mannitol, 0.5 to 10% by weight of croscarmellose sodium, 0.1 to 1% by weight of talc, and 0.1 to 3% by weight of magnesium stearate, filled into a gelatin capsule,
wherein the capsule comprises the lumateperone mono-tosylate in an amount equivalent to 1 to 40 mg of lumateperone free base;
wherein the disease or disorder is selected from a panic disorder, social anxiety disorder, obsessive-compulsive disorder, attention deficit disorder, attention deficit hyperactivity disorder, and behavioral disturbances associated with autism.
2 . The method of claim 1 , wherein the capsule comprises the lumateperone mono-tosylate in an amount equivalent to 1 to 10 mg of lumateperone free base.
3 . The method of claim 1 , wherein the capsule comprises the lumateperone mono-tosylate in an amount equivalent to 10 to 20 mg of lumateperone free base.
4 . The method of claim 1 , wherein the capsule comprises the lumateperone mono-tosylate in an amount equivalent to 20 to 30 mg of lumateperone free base.
5 . The method of claim 1 , wherein the capsule comprises the lumateperone mono-tosylate in an amount equivalent to about 14 mg of lumateperone free base.
6 . The method of claim 1 , wherein the capsule comprises the lumateperone mono-tosylate in an amount equivalent to about 28 mg of lumateperone free base.
7 . The method of claim 1 , wherein the disease or disorder is obsessive-compulsive disorder.
8 . The method of claim 1 , wherein the disease or disorder is attention deficit disorder or attention deficit hyperactivity disorder.
9 . The method of claim 1 , wherein the disease or disorder is a panic disorder or social anxiety disorder.
10 . The method of claim 1 , wherein the disease or disorder is behavioral disturbances associated with autism.
11 . The method of claim 3 , wherein the disease or disorder is obsessive-compulsive disorder.
12 . The method of claim 3 , wherein the disease or disorder is attention deficit disorder or attention deficit hyperactivity disorder.
13 . The method of claim 3 , wherein the disease or disorder is a panic disorder or social anxiety disorder.
14 . The method of claim 3 , wherein the disease or disorder is behavioral disturbances associated with autism.
15 . The method of claim 4 , wherein the disease or disorder is obsessive-compulsive disorder.
16 . The method of claim 4 , wherein the disease or disorder is attention deficit disorder or attention deficit hyperactivity disorder.
17 . The method of claim 4 , wherein the disease or disorder is a panic disorder or social anxiety disorder.
18 . The method of claim 4 , wherein the disease or disorder is behavioral disturbances associated with autism.
19 . A method for the treatment of a disease or disorder involving or mediated by the 5-HT 2A receptor, serotonin transporter (SERT), and/or dopamine D1/D2 receptor signaling pathways, comprising administering to a patient in need thereof a pharmaceutical capsule for oral administration, comprising lumateperone:
in mono-tosylate salt form, wherein the lumateperone mono-tosylate is in solid crystal form; and
wherein the capsule comprises a blend of 10 to 30% by weight of lumateperone mono-tosylate in solid crystal form, and one or more pharmaceutically acceptable diluents or carriers comprising one or more of (a) diluent/filler, (b) binder, (c) disintegrant, (d) lubricant, or (e) a glidant; and
wherein a single pharmaceutical capsule dissolves in 500 mL of 0.1 N aqueous hydrochloric acid to the extent of at least 85% after 15 minutes, and/or to the extent of at least 92% after 30 minutes, and/or to the extent of at least 94% after 45 minutes;
wherein the capsule comprises the lumateperone mono-tosylate in an amount equivalent to 1 to 40 mg of lumateperone free base; and
wherein the disease or disorder is selected from a panic disorder, social anxiety disorder, obsessive-compulsive disorder, attention deficit disorder, attention deficit hyperactivity disorder, and behavioral disturbances associated with autism, wherein the blend of the capsule does not comprise glyceryl monostearate.
20 . The method according to claim 19 , wherein the one or more pharmaceutically acceptable diluents or carriers are (a) a diluent/filler selected from the group consisting of cellulose, microcrystalline cellulose, dicalcium phosphate, and isomalt, (b) a binder selected from the group consisting of hydroxypropyl cellulose, hydroxypropyl methylcellulose, ethyl cellulose, methylcellulose, polyvinyl pyrrolidone, povidone, polyvinyl alcohol, gum arabic powder, gelatin, and pullulan, (c) a disintegrant selected from the group consisting of crospovidone, croscarmellose sodium, carmellose calcium, sodium starch glycolate, low substituted hydroxypropyl cellulose, and powdered agar, (d) a lubricant selected from the group consisting of magnesium stearate, calcium stearate, sucrose fatty acid ester, polyethylene glycol, talc, stearic acid, and sodium stearyl fumarate, and (e) a glidant selected from the group consisting of talc and silica.
21 . The method according to claim 19 , wherein the one or more pharmaceutically acceptable diluents or carriers are mannitol, croscarmellose sodium, talc, and magnesium stearate; and wherein the one or more pharmaceutically acceptable diluents or carriers and the lumateperone mono-tosylate are filled into a gelatin capsule.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 1, 2023
From: LI, PENG; DAVIS, ROBERT E.
To: INTRA-CELLULAR THERAPIES, INC.
Reel/Frame 065732/0306 →
Continuity (7)
Provisional Application
62779923
· Dec 14, 2018
Provisional Application
62725948
· Aug 31, 2018
References Cited (400)
US 2490813A
· Hughes et al.
· 1949
[cited by applicant]
US 3299078A
· Pachter
· 1967
[cited by applicant]
US 3813392A
· Sellstedt et al.
· 1974
[cited by applicant]
US 3914421A
· Rajagopalan
· 1975
[cited by applicant]
US 4001263A
· Plattner et al.
· 1977
[cited by applicant]
US 4115577A
· Rajagopalan
· 1978
[cited by applicant]
US 4136145A
· Fuchs et al.
· 1979
[cited by applicant]
US 4183936A
· Rajagopalan
· 1980
[cited by applicant]
US 4219550A
· Rajagopalan
· 1980
[cited by applicant]
US 4238607A
· Rajagopalan
· 1980
[cited by applicant]
US 4389330A
· Tice et al.
· 1983
[cited by applicant]
US 4522944A
· Doria et al.
· 1985
[cited by applicant]
US 4530840A
· Tice et al.
· 1985
[cited by applicant]
US 4849246A
· Schmidt
· 1989
[cited by applicant]
US 4971971A
· Tokunaga et al.
· 1990
[cited by applicant]
US 4985432A
· Tokunaga et al.
· 1991
[cited by applicant]
US 5114976A
· Norden
· 1992
[cited by applicant]
US 5151419A
· Perenyi et al.
· 1992
[cited by applicant]
US 5538739A
· Bodmer et al.
· 1996
[cited by applicant]
US 5576460A
· Buchwald et al.
· 1996
[cited by applicant]
US 5629003A
· Horstmann et al.
· 1997
[cited by applicant]
US 5648539A
· Goodbrand
· 1997
[cited by applicant]
US 5648542A
· Goodbrand et al.
· 1997
[cited by applicant]
US 5654482A
· Goodbrand
· 1997
[cited by applicant]
US 5705697A
· Goodbrand et al.
· 1998
[cited by applicant]
US 5723669A
· Goodbrand et al.
· 1998
[cited by applicant]
US 5723671A
· Goodbrand et al.
· 1998
[cited by applicant]
US 5763476A
· Delbressine et al.
· 1998
[cited by applicant]
US 5834493A
· Gil Quintero et al.
· 1998
[cited by applicant]
US 5847166A
· Buchwald et al.
· 1998
[cited by applicant]
US 5902901A
· Goodbrand et al.
· 1999
[cited by applicant]
US 5922338A
· Erich et al.
· 1999
[cited by applicant]
US 5948430A
· Zerbe et al.
· 1999
[cited by applicant]
US 6043370A
· Kubo et al.
· 2000
[cited by applicant]
US 6166226A
· Buchwald et al.
· 2000
[cited by applicant]
US 6221335B1
· Foster
· 2001
[cited by applicant]
US 6235936B1
· Buchwald et al.
· 2001
[cited by applicant]
US 6307087B1
· Buchwald et al.
· 2001
[cited by applicant]
US 6323366B1
· Wolfe et al.
· 2001
[cited by applicant]
US 6395916B1
· Buchwald et al.
· 2002
[cited by applicant]
US 6407092B1
· Hester et al.
· 2002
[cited by applicant]
US 6419952B2
· Wong et al.
· 2002
[cited by applicant]
US 6440710B1
· Keinan et al.
· 2002
[cited by applicant]
US 6448243B1
· Kitazawa et al.
· 2002
[cited by applicant]
US 6465693B2
· Buchwald et al.
· 2002
[cited by applicant]
US 6541639B2
· Zhou et al.
· 2003
[cited by applicant]
US 6544559B2
· Mesens et al.
· 2003
[cited by applicant]
US 6548493B1
· Robichaud et al.
· 2003
[cited by applicant]
US 6552017B1
· Robichaud et al.
· 2003
[cited by applicant]
US 6552024B1
· Chen et al.
· 2003
[cited by applicant]
US 6603008B1
· Ando et al.
· 2003
[cited by applicant]
US 6699852B2
· Robichaud et al.
· 2004
[cited by applicant]
US 6713471B1
· Robichaud et al.
· 2004
[cited by applicant]
US 6759554B2
· Buchwald et al.
· 2004
[cited by applicant]
US 6762329B2
· Marcoux et al.
· 2004
[cited by applicant]
US 6828314B2
· Frank et al.
· 2004
[cited by applicant]
US 6849619B2
· Robichaud et al.
· 2005
[cited by applicant]
US 6849640B2
· Ennis et al.
· 2005
[cited by applicant]
US 6867298B2
· Buchwald et al.
· 2005
[cited by applicant]
US 6888032B2
· Buchwald et al.
· 2005
[cited by applicant]
US 6946560B2
· Buchwald et al.
· 2005
[cited by applicant]
US 7026498B2
· Buchwald et al.
· 2006
[cited by applicant]
US 7071186B2
· Robichaud et al.
· 2006
[cited by applicant]
US 7081455B2
· Robichaud et al.
· 2006
[cited by applicant]
US 7109339B2
· Lee et al.
· 2006
[cited by applicant]
US 7115784B2
· Buchwald et al.
· 2006
[cited by applicant]
US 7183282B2
· Robichaud et al.
· 2007
[cited by applicant]
US 7223879B2
· Buchwald et al.
· 2007
[cited by applicant]
US RE39679E
· Robichaud et al.
· 2007
[cited by applicant]
US RE39680E
· Robichaud et al.
· 2007
[cited by applicant]
US 7238690B2
· Robichaud et al.
· 2007
[cited by applicant]
US 7247731B2
· Buchwald et al.
· 2007
[cited by applicant]
US 7323608B2
· Buchwald et al.
· 2008
[cited by applicant]
US 7375226B2
· Jolidon et al.
· 2008
[cited by applicant]
US 7517990B2
· Ito et al.
· 2009
[cited by applicant]
US 7592454B2
· Lee et al.
· 2009
[cited by applicant]
US 7614727B2
· Hori
· 2009
[cited by applicant]
US 7645752B2
· McDevitt et al.
· 2010
[cited by applicant]
US 7998971B2
· Barlow et al.
· 2011
[cited by applicant]
US 8309722B2
· Tomesch et al.
· 2012
[cited by applicant]
US 8414922B2
· Bryson et al.
· 2013
[cited by applicant]
US 8461148B2
· Hollander
· 2013
[cited by applicant]
US 8598119B2
· Mates et al.
· 2013
[cited by applicant]
US 8603514B2
· Yang et al.
· 2013
[cited by applicant]
US 8648077B2
· Tomesch et al.
· 2014
[cited by applicant]
US 8652378B1
· Yang et al.
· 2014
[cited by applicant]
US 8697700B2
· Surman et al.
· 2014
[cited by applicant]
US 8779139B2
· Tomesch et al.
· 2014
[cited by applicant]
US 8791138B2
· Seeman et al.
· 2014
[cited by applicant]
US 8835459B2
· Kottayil et al.
· 2014
[cited by applicant]
US 8900497B2
· Yang et al.
· 2014
[cited by applicant]
US 8900498B2
· Yang et al.
· 2014
[cited by applicant]
US 8906277B2
· Yang et al.
· 2014
[cited by applicant]
US 8993572B2
· Mates et al.
· 2015
[cited by applicant]
US 9108340B2
· Yang et al.
· 2015
[cited by applicant]
US 9168258B2
· Mates et al.
· 2015
[cited by applicant]
US 9199995B2
· Tomesch et al.
· 2015
[cited by applicant]
US 9216175B2
· Amancha et al.
· 2015
[cited by applicant]
US 9315504B2
· Tomesch et al.
· 2016
[cited by applicant]
US 9371324B2
· Mates et al.
· 2016
[cited by applicant]
US 9393192B2
· Yam et al.
· 2016
[cited by applicant]
US 9427412B2
· Bryson et al.
· 2016
[cited by applicant]
US 9428506B2
· Mates et al.
· 2016
[cited by applicant]
US 9567327B2
· Xiong et al.
· 2017
[cited by applicant]
US 9586960B2
· Tomesch et al.
· 2017
[cited by applicant]
US 9616061B2
· Mates et al.
· 2017
[cited by applicant]
US 9708322B2
· Li et al.
· 2017
[cited by applicant]
US 9745300B2
· Mates et al.
· 2017
[cited by applicant]
US 9751883B2
· Tomesch et al.
· 2017
[cited by applicant]
US 9956227B2
· Vanover et al.
· 2018
[cited by applicant]
US RE48825E
· Tomesch et al.
· 2021
[cited by applicant]
US RE48839E
· Mates et al.
· 2021
[cited by applicant]
US 20010008942A1
· Buchwald et al.
· 2001
[cited by applicant]
US 20010036472A1
· Wong et al.
· 2001
[cited by applicant]
US 20030065187A1
· Buchwald et al.
· 2003
[cited by applicant]
US 20040034015A1
· Robichaud et al.
· 2004
[cited by applicant]
US 20040092534A1
· Yam et al.
· 2004
[cited by applicant]
US 20040127482A1
· Robichaud et al.
· 2004
[cited by applicant]
US 20040142970A1
· Chung et al.
· 2004
[cited by applicant]
US 20050058703A1
· Chang et al.
· 2005
[cited by applicant]
US 20050166771A1
· Gygi et al.
· 2005
[cited by applicant]
US 20050222209A1
· Zeldis et al.
· 2005
[cited by applicant]
US 20060205787A1
· Muller et al.
· 2006
[cited by applicant]
US 20070049759A1
· Ghosh et al.
· 2007
[cited by applicant]
US 20080069885A1
· Mesens et al.
· 2008
[cited by applicant]
US 20080132552A1
· Kleinman et al.
· 2008
[cited by applicant]
US 20080194592A1
· Mates et al.
· 2008
[cited by applicant]
US 20080280941A1
· Lourtie
· 2008
[cited by applicant]
US 20090076159A1
· Czarnik
· 2009
[cited by applicant]
US 20090209608A1
· Czarnik
· 2009
[cited by applicant]
US 20100159033A1
· Gant et al.
· 2010
[cited by applicant]
US 20110269777A1
· Bachurin et al.
· 2011
[cited by applicant]
US 20140088083A1
· Hollander
· 2014
[cited by applicant]
US 20150004237A1
· Edgar et al.
· 2015
[cited by applicant]
US 20150031804A1
· Shiramizu et al.
· 2015
[cited by applicant]
US 20150038519A1
· Mates et al.
· 2015
[cited by applicant]
US 20200157100A1
· Li
· 2020
[cited by applicant]
US 20200392135A1
· Wennogle et al.
· 2020
[cited by applicant]
US 20210008065A1
· Li et al.
· 2021
[cited by applicant]
US 20230372336A1
· Dutheil et al.
· 2023
[cited by applicant]
EP 0058481
· 1982
[cited by applicant]
EP 0856508
· 1998
[cited by applicant]
EP 0976732
· 2000
[cited by applicant]
EP 1245553
· 2002
[cited by applicant]
EP 1254884
· 2002
[cited by applicant]
EP 1539115
· 2005
[cited by applicant]
EP 1564671
· 2005
[cited by applicant]
GB 1476087
· 1977
[cited by applicant]
GB 2145422
· 1985
[cited by applicant]
RU 2465267
· 2012
[cited by applicant]
WO WO1995013814
· 1995
[cited by applicant]
WO WO1999043643
· 1999
[cited by applicant]
WO WO2000002887
· 2000
[cited by applicant]
WO WO2000064899
· 2000
[cited by applicant]
WO WO2002059129
· 2002
[cited by applicant]
WO WO2003014118
· 2003
[cited by applicant]
WO WO2005030214
· 2005
[cited by applicant]
WO WO2014110322
· 2014
[cited by applicant]
WO 2016128411A1
· 2016
[cited by applicant]
WO WO2017117514
· 2017
[cited by applicant]
WO WO2017132408
· 2017
[cited by applicant]
WO WO2018106916
· 2018
[cited by applicant]
WO WO2018175969
· 2018
[cited by applicant]
WO WO2019102240
· 2019
[cited by applicant]
Urso et al (European Review for Medical and Pharmacological Sciences, 2002, vol. 6, pp. 33-44) (Year: 2002).
[cited by examiner]
Sowa-Kucma et al (International Journal of Molecular Sciences, 2024, vol. 25, pp. 1-13) (Year: 2024).
[cited by examiner]
Glube et al (Results in Pharma Sciences, 2013, vol. 3, pp. 1-6) (Year: 2013).
[cited by examiner]
“Study of a Novel Antipsychotic ITI-007 in Schizophrenia,” Clinical Trials.gov, 6 pages, Dec. 26, 2011.
[cited by applicant]
“Securities,”
[cited by applicant]
Alvir, et al., “Clozapine-Induced Agranulocytosis,”
[cited by applicant]
Angst et al. “Prevalence and Characteristics of Undiagnosed Bipolar Disorders in Patients With a Major Depressive Episode”,
[cited by applicant]
Avendano, et al., “The problem of the existence of C(Ar)—H . . . N Intramolecular Hydrogen Bonds in a Family of 9-Azaphenyl-9H-carbazoles,”
[cited by applicant]
Baille, T.A., “The Use of Stable Isotopes in Pharmacological Research,”
[cited by applicant]
Barman et al., “Newer antipsychotics: Brexpiprazole, cariprazine, and lumateperone: A pledge or another unkept promise?”,
[cited by applicant]
Beletskaya, et al., “Pd- and Cu-catalyzed selective arylation of benzotriazole,” Tetrahedron Letters, vol. 39, pp. 5617-5620, (1998).
[cited by applicant]
Bennett, et al., “Cecil Textbook of Medicine,” 20th Edition, vol. 1, pp. 1004-1010, (1996).
[cited by applicant]
Berger, et al., “Synthesis of Some Conformationally Restricted Analogs of Fentanyl,” Journal of Medicinal Chemistry, vol. 20, No. 4, pp. 600-602, (1977).
[cited by applicant]
Boger, et al., “Inverse Electron Demand Diels-Alder Reactions of Heterocyclic Aza Dienes. Studies on the Total Synthesis of Lavendamycin: Investigative Studies on the Preparation of the CDE β-Carboline Ring System and A…
[cited by applicant]
Borghans et al., “Animal Models for Posttraumatic Stress Disorder: An Overview of What is Used in Research,”
[cited by applicant]
Bowman, et al., “Intramolecular Aromatic Substitution (SRN1) Reactions—Use of Entrainment for the Preparation of Benzothiazoles,” Tetrahedron Letters, vol. 23, pp. 5093-5096, (1982).
[cited by applicant]
Bowman, et al., “Copper (1) Catalysed Aromatic Nucleophilic Substitution: A Mechanistic and Synthetic Comparison with the SRN 1 Reaction,” Tetrahedron Letters, vol. 25, No. 50, pp. 5821-5824, (1984).
[cited by applicant]
Bowman, et al.,“Synthesis of 1H-quinazoline-4-ones Using Intramolecular Aromatic Nucelophilic Substitution,” Arkivoc, vol. x, pp. 434-442 (2003).
[cited by applicant]
Bremner, et al., “Neuroimaging of Posttraumatic Stress Disorder”, Psychiatric Annals Journal, vol. 28, No. 8, p. 445-450, (1998).
[cited by applicant]
Browne, T.R., “Stable Isotope Techniques in Early Drug Development: An Economic Evaluation,” J. Clin. Pharmacol., vol. 38, pp. 213-220, (1998).
[cited by applicant]
Bryan-Lluka, et al., “Potencies of Haloperidol Metabolites as Inhibitors of the Human Noradrenaline, Dopamine and Serotonin Transporters in Transfected COS-7 Cells,” Naunyn-Shemiedeberg's Arch Pharmacol, vol. 360, pp. 1…
[cited by applicant]
Byrn, et al., “Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations,” Pharmaceutical Research, vol. 12, No. 7, pp. 945-954, (1995).
[cited by applicant]
Caira, M.R., “Crystalline Polymorphism of Organic Compounds,” Topics in Current Chemistry, vol. 198, p. 163-203, (1998).
[cited by applicant]
Cherrah, et al., “Study of Deuterium Isotope Effects on Protein Binding by Gas Chromatography/Mass Spectrometry. Caffeine and Deuterated Isotopomers,” Biomedical and Environmental Mass Spectrometry, vol. 14, pp. 653-657…
[cited by applicant]
Correll et al., “Efficacy and Safety of Lumateperone for Treatment of Schizophrenia A Randomized Clinical Trial”,
[cited by applicant]
Crawford, et al., “Copper-Catalyzed Amidations of Bromo Substituted Furans and Thiophenes,” Tetrahedron Letters, vol. 43, pp. 7365-7368, (2002).
[cited by applicant]
Darmani, et al., “Do Functional Relationships Exist Between 5-HT1A and 5-HT2 Receptors?” Pharmacology and Biochemistry & Behavior, vol. 36, pp. 901-906, (1990).
[cited by applicant]
Davis et al., “ITI-007: A Novel Treatment for Behavioral Disturbances Associated with Dementia and Related Disorders,” Clinical Trials in Alzheimer's Disease (CTAD) Congress 2014 (2014) (poster presentation).
[cited by applicant]
Davis, et al., “ITI-007 demonstrates brain occupancy at serotonin 5-HT2A and dopamine D2 receptors and serotonin transporters using positron emission tomography in healthy volunteers,” Psychopharmacology, vol. 232, pp. …
[cited by applicant]
Davis, et al., “ITI-007 in the Treatment of Schizophrenia: From Novel Pharmacology to Clinical Outcomes,” Expert Review of Neurotherapeutics, vol. 16, No. 6, pp. 601-614, (2016).
[cited by applicant]
Davis, et al., “Lumateperone (ITI-007), A Novel Drug in Development for the Treatment of Agitation in Patients with Dementia, including Alzheimer's Disease: Rationale and Clinical Design,” The Journal of Prevention of A…
[cited by applicant]
Davis et al., “Rationale for the Development of Low Doses of ITI-007 for the Treatment of Behavioral Disturbances Associated with Dementia,” The Journal of Prevention of Alzheimer's Disease, 2(4):302 (2015) (Clinical Tr…
[cited by applicant]
Dhawan et al., “Sleep-related Problems of Parkinson's Disease,”
[cited by applicant]
Dyck, et al., “Effects of Deuterium Substitution on the Catabolismof β-Phenylethylamine: An In Vivo Study,” Journal of Neurochemistry, vol. 46, Issue 2, pp. 399-404, (1986).
[cited by applicant]
Edinoff et al., “Lumateperone for the Treatment of Schizophrenia”,
[cited by applicant]
Evindar, et al., “Copper- and Palladium-Catalyzed Intramolecular Aryl Guanidinylation: An Efficient Method for the Synthesis of 2-Aminobenzimidazoles”, Organic Letters, vol. 5, No. 2, pp. 133-136, (2003).
[cited by applicant]
Ezquerra, et al., “Efficient Reagents for the Synthesis of 5-, 7-, and 5, 7-Substitued Indoles Starting from Aromatic Amines: Scope and Limitations”, J. Org. Chem., vol. 61, pp. 5804-5812, (1996).
[cited by applicant]
Fawcett, J., “Posttraumatic Stress Disorder, Stress, and Happiness”, Psychiatric Annals Journal, vol. 28, No. 8, pp. 427-428, (1998).
[cited by applicant]
Fee, et al., “Copper (II)-Promoted Solvolyses of Nickel (II) Complexes III. Tetradentate Schiff Base Ligands Containing Various Diamine Segments,” Aust. J. Chem., vol. 26, pp. 1475-1485, (1973).
[cited by applicant]
Ferreira, et al., “Novel Synthetic Routes to Thienocarbazoles Via Palladium or Copper Catalyzed Amination or Amidation of Arylhalides and Intramolecular Cyclization”, Tetrahedron, vol. 58, pp. 7943-7949, (2002).
[cited by applicant]
Finet, et al., “Recent Advances in Ullmann Reaction: Copper (II) Diacetate Catalysed N-, )- and S-arylation Involving Polycoordinate Heteroatomic Derivatives,” Current Organic Chemistry, vol. 6, pp. 597-626, (2002).
[cited by applicant]
Fletcher et al., “Perceiving is Believing: A Bayesian Approach to Explaining the Positive Symptoms of Schizophrenia,”
[cited by applicant]
Foster, A.B., “Deuterium Isotope Effects in the Metabolism of Drugs and Xenobiotics: Implications for Drug Design,” Advances in Drug Research, vol. 14, pp. 1-40, (1985).
[cited by applicant]
Foster, et al., “Acetylcholinesterase Inhibitors Reduce Spreading Activation in Dementia,” Neuropsychologia, vol. 50, pp. 2093-2099, (2012).
[cited by applicant]
Foster et al., “Emerging Approaches for Treatment of Schizophrenia: Modulation of Cholinergic Signaling”,
[cited by applicant]
Friedman, M.J.., “Current and Future Drug Treatment for Posttraumatic Stress Disorder Patients”, Psychiatric Annals Journal, vol. 28, No. 8, pp. 464-468, (1998).
[cited by applicant]
Goodbrand, et al., “Ligand-Accelerated Catalysis of the Ullmann Condensation: Application to Hole Conducting Triarylamines,” J. Org. Chem., vol. 64, pp. 670-674, (1999).
[cited by applicant]
Gouyette, A., “Synthesis of Deuterium-labelled Elliptinium and its Use in Metabolic Studies,” Biomedical and Environmental Mass Spectrometry, vol. 15, pp. 243-247, (1988).
[cited by applicant]
Gramigna, J, “Lumateperone Safe, Effective for Depressive Symptoms Among Patients with Bipolar Disorders,” American Society of Clinical Psychopharmacology Annual Meeting, Jun. 2, 2020, 3 pages.
[cited by applicant]
Hackam, et al., “Translation of Research Evidence from Animals to Humans,” JAMA, vol. 296, No. 14, pp. 1731-1732, (2006).
[cited by applicant]
Hamann, et al., “Systematic Variation of Bidentate Ligands Used in Aryl Halide Amination. Unexpected Effects of Steric, Electronic, and Geometric Perturbations”, J. Am. Chem. Soc., vol. 120, pp. 3694-3703, (1998).
[cited by applicant]
Harbert, et al., “Neuroleptic Activity in 5-Aryltetrahydro-y-carbolines”, J. Med. Chem., vol. 23, pp. 635-643, (1980).
[cited by applicant]
Hartwig, J., “Palladium-Catalyzed Amination of Aryl Halides: Mechanism and Rational Catalyst Design,” Synlett, pp. 329-340, (1996).
[cited by applicant]
Harvey, et al., “Serotonin and Stress: Protective or Malevolent Actions in the Biobehavioral Response to Repeated Trauma?,” Annals of the New York Academy of Sciences, vol. 1032, pp. 267-272, (2004); DOI: 10.1196/annals…
[cited by applicant]
Haskins, N.J., “The Application of Stable Isotopes in Biomedical Research,” Biological Mass Spectrometry, vol. 9, No. 7, pp. 269-277, (1982).
[cited by applicant]
Hassan, et al., “Aryl-aryl Bond Formation One Century After the Discovery of the Ullmann Reaction,” Chem. Rev., vol. 102, pp. 1359-1469, (2002).
[cited by applicant]
Hlavinka, E., “Schizophrenia Tx Eases Depression in Bipolar Disorder: Lumateperone Offers Greater Rate of Response, Remission versus Placebo,” Medpage Today, 7 pages, (2020); https://www.medpagetoday.com/meetingcoverage…
[cited by applicant]
Honma, S., et al., “The Metabolism of Roxatidine Acetate Hydrochloride: Liberation of Deuterium from the Piperidine Ring during Hydroxylation,” Drug Metabolism and Disposition, vol. 15, No. 4, pp. 551, (1987).
[cited by applicant]
Howes et al., “Glutamate and dopamine in schizophrenia: An update for the 21st century”, J. Psychopharmacol., 29(2): 97-115 (2015).
[cited by applicant]
Howland, R.H., “Deuterated Drugs,” Journal of Psychosocial Nursing and Mental Health Services, 53(9): 13-16 (2015).
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2013/036514 issued Oct. 14, 2014.
[cited by applicant]
International Search Report issued in International Application No. PCT/US2008/003340, mailed Aug. 8, 2008, 3 pages.
[cited by applicant]
International Search Report issued in International Application No. PCT/US2009/001608, mailed Apr. 27, 2009, 3 pages.
[cited by applicant]
International Search Report issued in International Application No. PCT/US2009/003261, mailed Jul. 16, 2009.
[cited by applicant]
International Search Report issued in International Application No. PCT/US2011/00719, mailed Jul. 5, 2011, 3 pages.
[cited by applicant]
International Search Report issued in International Application No. PCT/US2013/036515, mailed Aug. 13, 2013, 3 pages.
[cited by applicant]
International Search Report issued in International Application No. PCT/US2013/036514, mailed Aug. 16, 2013, 3 pages.
[cited by applicant]
International Search Report issued in International Application No. PCT/US2013/036512, mailed Aug. 19, 2013, 4 pages.
[cited by applicant]
International Search Report issued in International Application No. PCT/US2015/024340, mailed Jun. 25, 2015, 2 pages.
[cited by applicant]
International Search Report issued in International Application No. PCT/US2015/024345, mailed Jun. 25, 2015, 3 pages.
[cited by applicant]
International Search Report issued in International Application No. PCT/US2017/054962, date mailed Nov. 27, 2017, 3 pages.
[cited by applicant]
Intra-Cellular Therapies, Inc., “Corporate Presentation” (Sep. 24, 2019), downloaded from https://ir.intracellulartherapies.com/static-files/93b08960-f01c-4864-aa22-8cadb3539753 (last accessed Mar. 13, 2023).
[cited by applicant]
Ito, et al., “Studies of Organic Catalytic Reactions. VI. The Function of Pyridine and Copper in the Rosenmund-von Braun Reaction,” Bulletin of the Chemical Society of Japan, vol. 41, pp. 419-423, (1968).
[cited by applicant]
Izrayelit, L., “Schizoaffective Disorder and PTSD Successfully Treated With Olanzapine and Supportive Psychotherapy”, Psychiatric Annals Journal, vol. 28, No. 8, pp. 424-426, (1998).
[cited by applicant]
Ji, et al., “Selective Amination of Polyhalopyridines Catalyzed by a Palladium-xantphos Complex,” Organic Letters, vol. 5, No. 24, pp. 4611-4614, (2003).
[cited by applicant]
Juorio, A.V., et al., “Effects of Acute and Chronic Phenelzine on Regional Monoamine Metabolism in Rats and its Potentiation by Deuterium Substitution,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 333, No. 3, p…
[cited by applicant]
Kahn et al., “Residual Symptoms of Schizophrenia. What are Realistic Treatment Goals? Lingering Symptoms Require you to Evaluate Pharmacotherapy and Offer Psychosocial Interventions,”
[cited by applicant]
Kametani, et al., “A Novel Synthesis of Indole Derivatives,” Heterocycles, vol. 14 No. 3, pp. 277-280, (1980).
[cited by applicant]
Kang, et al., “Copper-catalyzed N-arylation of Aryl Iodides with Benzamides or Nitrogen Heterocycles in the Presence of Ethylendiamine,” Synlett, No. 3, pp. 427-430, (2002).
[cited by applicant]
Kay, et al., “The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia,” Schizophrenia Bulletin, vol. 13, No. 2, pp. 261-276, (1987).
[cited by applicant]
Kendrick, “The newer, ‘atypical’ antipsychotic drugs—their development and current therapeutic use”,
[cited by applicant]
Kessler, et al., “Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication,” Arch Gen Psychiatry, vol. 62, pp. 593-602, (2005).
[cited by applicant]
Khorana, et al., “Gamma-Carbolines: Binding at 5-HT5A Serotonin Receptors,” Bioorganic & Medicinal Chemistry, vol. 11, pp. 717-722, p. 718 Table 1, (2003).
[cited by applicant]
Kiyomori, et al., “An Efficient Copper-catalyzed Coupling of Aryl Halides with Imidazoles,” Tetrahedron Letters, vol. 40, pp. 2657-2660, (1999).
[cited by applicant]
Klapars, et al., “A General and Efficient Copper Catalyst for the Amidation of Aryl Halides and the N-arylation of Nitrogen Heterocycles,” J. Am. Chem. Soc., vol. 123, pp. 7727-7729, (2001).
[cited by applicant]
Klapars, et al., “A General and Efficient Copper Catalyst for the Amidation of Aryl Halides,” J. Am. Chem. Soc., vol. 124, pp. 7421-7428, (2002).
[cited by applicant]
Kondratov, et al., “Nucelophilic Substitution in the Aromatic Series. Lv. Reaction of o-nitrochlorobenzene with Ammonia in the Presence of Copper Compounds,” Zhurnal Organidreskoi Khimii, vol. 51, No. 11, pp. 2387-2390,…
[cited by applicant]
Koppel, et al., “Optimal Treatment of Alzheimer's Disease Psychosis: Challenges and Solutions,” Neuropsychiatric Disease and Treatment, vol. 10, pp. 2253-2262, (2014).
[cited by applicant]
Korczak et al., “Use of selective serotonin reuptake inhibitor medications for the treatment of child and adolescent mental illness”,
[cited by applicant]
Kwong, et al., “Mild and Efficient Copper-catalyzed Amination of Aryl Bromides with Primary Alkylamines,” Organic Letters, vol. 5, No. 6, pp. 793-796, (2003).
[cited by applicant]
Lebert, et al., “Trazodone in Fronto-Temporal Dementia,” Research and Practice in Alzheimer's Disease, vol. 11, pp. 356-360, (2006).
[cited by applicant]
Lee, et al. “Novel, Highly Potent, Selective 5-HT2A/D2 Receptor Antagonists as Potential Atypical Antipsychotics,” Bioorg. Med. Chem. Lett., vol. 13, pp. 767-770, (2003).
[cited by applicant]
Li, et al., “Discovery of a Tetracyclic Quinoxaline Derivative as a Potent and Orally Active Multifunctional Drug Candidate for the Treatment of Neuropsychiatric and Neurological Disorders,” Journal of Medicinal Chemist…
[cited by applicant]
Lieberman, et al., “ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial,” Biol. Psychiatry, vol. 79, No. 12, pp. 952-961, (2015).
[cited by applicant]
Lin, et al., “Dosage and Duration of Antipsychotic Treatment in Demented Outpatients with Agitation or Psychosis,” Journal of the Formosan Medical Association, vol. 114, pp. 147-153, (2015).
[cited by applicant]
Lipschitz, et al., “Childhood Posttraumatic Stress Disorder: A Review of Neurobiologic Sequelae,” Psychiatric Annals Journal, vol. 28, No. 8, pp. 452-457, (1998).
[cited by applicant]
Liriano et al., “Ketamine as treatment for post-traumatic stress disorder: a review.” Drugs in Context, vol. 8, 7 pages (2019).
[cited by applicant]
Lopez, et al., “Psychiatric Symptoms Vary with the Severity of Dementia in Probably Alzheimer's Disease,” J. Neuropsychiatry Clin. Neurosc., vol. 15, No. 3, pp. 346-353, (2003).
[cited by applicant]
Louie, et al., “Palladium-Catalyzed Synthesis of Arylamines from Aryl Halides, Mechanistic Studies lead to Coupling in the Absence of Tin Reagents,” Tetrahedron Letters, vol. 36, No. 21, pp. 3609-3612, (1995).
[cited by applicant]
Lounkine, et al., “Formal Concept Analysis for the Identification of Molecular Fragment Combinations Specific for Active and Highly Potent Compounds,” J. Med. Chem., vol. 51, No. 17, pp. 5342-5348, (2008).
[cited by applicant]
Madhusoodanan, et al., “Pharmacological Management of Behavioral Symptoms Associated with Dementia,” World J. Psychiatr., vol. 4, No. 4, pp. 72-79, (2014).
[cited by applicant]
Makadia et al., “Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier,”
[cited by applicant]
March, et al., Advanced Organic Chemistry; Reactions, Mechanisms and Structures, Fourth Edition, pp. 910-911, (1992).
[cited by applicant]
Marcoux, et al., “A General Copper-catalyzed Synthesis of Diaryl Ethers,” J. Am. Chem. Soc., vol. 119, pp. 10539-10540, (1997).
[cited by applicant]
Marek et al., “Synergistic Action of 5-HT2A Antagonists and Selective Serotonin Reuptake Inhibitors in Neuropsychiatric Disorders”,
[cited by applicant]
Marek et al. Synergistic Action of 5-HT2A Antagonists and Selective Serotonin Reuptake Inhibitors in Neuropsychiatric Disorders. Neuropsychopharmacology, 2003. vol. 28, pp. 402-412. (Year: 2003).
[cited by applicant]
McConnell & AW Basit, “Modified-Release Oral Drug Delivery”,
[cited by applicant]
Mohamed, et al., “Pharmacotherapy of PTSD in the U.S. Department of Veterans Affairs: Diagnostic- and Symptom-guided Drug Selection,” J. Clin. Psychiatry, vol. 69, pp. 959-965, (2008).
[cited by applicant]
Morgan, et al., “Acoustic Startle in Individuals With Posttraumatic Stress Disorder,” Psychiatric Annals Journal, vol. 28, Issue 8, pp. 430-434, (1998).
[cited by applicant]
Müller et al., “Detection of Depression in Acute Schizophrenia: Sensitivity and Specificity of 2 Standard Observer Rating Scales,”
[cited by applicant]
Mulrooney, et al., “Recent Developments in Copper-catalyzed N-Arylation with Aryl Halides,” Essay—University of Pennsylvania, (2004).
[cited by applicant]
Murakami, et al., “Fischer Indolization of Ethyl Pyruvate 2-[2-(Trifluoromethyl) phenyl]-phenylhydrazone and New Insight into the Mechanism of the Goldberg Reaction,” Chem. Pharm. Bull, vol. 43, No. 8, pp. 1281-1286, (1…
[cited by applicant]
Nagai, et al., “Synthesis of 2,3,4,4a,5,9b-hexahydro-1H-pyrido[4,3-b] indole Derivatives and Their Central Nervous System Activities,” Journal of Medicinal Chemistry, vol. 22, No. 6, pp. 677-683, (1979).
[cited by applicant]
Nihon rounen igaku zasshi, vol. 48, No. 3, pp. 195-204, (2011 nen). Partial English translation only, 2 pages.
[cited by applicant]
Noble et al., “The Opioid Receptors as Targets for Drug Abuse Medication,”
[cited by applicant]
O'Gorman, et al., “Lumateperone (ITI-007): A Novel Investigational Agent with Broad Therapeutic Potential Across Multiple Neuropsychiatric Disorders,” Poster p. 1.g.038, European College of Neuropsychopharmacology (ECNP…
[cited by applicant]
Palanisamy, M. et al., “Cellulose-Based Matrix Microspheres of Prednisolone Inclusion Complex; Preparation and Characterization.” American Association of Pharmaceutical Scientists PharmSciTech, vol. 12, No. 1, pp. 388-4…
[cited by applicant]
Perlis et al., “Clinical Features of Bipolar Depression Versus Major Depressive Disorder in Large Multicenter Trials”,
[cited by applicant]
Pieniaszek, et al., “Moricizine Bioavailability via Simultaneous Dual, Stable Isotope Administration: Bioequivalence Implications,” J. Clin. Pharmacol., vol. 39, pp. 817-825, (1999).
[cited by applicant]
Pine et al., “Dopamine, Time, and Impulsivity in Humans,”
[cited by applicant]
Pond, et al., “Stereospecific Reduction of Haloperidol in Human Tissues,” Biochemical Pharmacology, vol. 44, No. 5, pp. 867-871, (1992).
[cited by applicant]
Press Release, “Intra-Cellular Therapies Announces Additional Results from Phase I/II Clinical Trial for ITI-007 in Healthy Geriatric Subjects and Patients With Dementia,” Intra-Cellular Therapies, Press Release Date: N…
[cited by applicant]
“Protection for the Amino Group,” Protective Groups in Organic Synthesis, Third Edition, John Wiley & Sons, Inc., pp. 494-505, (1999).
[cited by applicant]
Rackova, et al., “Free Radical Scavenging and Antioxidant Activities of Substituted Hexahydropyridoindoles. Quantitative Structure-Activity Relationships.” Journal of Medicinal Chemistry, vol. 49, No. 8, pp. 2543-2548, …
[cited by applicant]
Rainer, M.K., “Risperidone Long-acting Injection: A Review of its Long Term Safety and Efficacy,” Neuropsychiatric Disease and Treatment, vol. 4, No. 5, pp. 919-927, (2008).
[cited by applicant]